During a Community Case Forum event, Antoinette R. Tan, MD, MHS, discussed the DESTINY-Breast04 and DESTINY-Breast06 trials ...

Less than three weeks after AstraZeneca and Daiichi Sankyo reported positive results for oncology powerhouse Enhertu in a ...

England’s drug approval body has resisted pressure from pharmaceutical companies to loosen its process for recommending drugs ...

Treatment with an Enhertu regimen significantly improved pathologic complete responses for patients with high-risk ...

AstraZeneca and Daiichi Sankyo's anti-HER2 drug Enhertu has been shown to provide a benefit in a phase 3 trial in early-stage ...

The trial’s primary endpoint is pCR, with secondary endpoints including event-free survival (EFS), overall survival, safety, ...

A combination of the HER2 agent, called disitamab vedotin, and Junshi Biosciences’ PD-1 inhibitor toripalimab outperformed ...

Topline results from the Phase III DESTINY-Breast11 trial show that Enhertu (trastuzumab deruxtecan) followed by paclitaxel, ...

Camizestrant with a CDK 4/6 inhibitor had a statistically significant and clinically meaningful improvement in PFS in HR+/HER2– advanced breast cancer. Dr. Debu Tripathy breaks down the FDA approval ...

Enliven Therapeutics has decided against taking its phase 1-stage solid tumor drug into further development next year in ...

AstraZeneca (AZ) and Daiichi Sankyo have shared positive results from a late-stage study of their HER2-directed antibody drug ...

First Phase III trial to demonstrate benefit of ENHERTU in early breast cancer WILMINGTON, Del.--(BUSINESS WIRE)-- Positive high-level results from the DESTINY-Breast11 Phase III trial showed ...